MKI67 and pancreatic neuroendocrine tumor: Ki67 > 10% as predictor for shorter PFS in si-NET was also shown in the Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumors (CLARINET FORTE) study [31].